Literature DB >> 912827

Neural regulation of renin release: experimental evidence and clinical implications in arterial hypertension.

A S Zanchetti.   

Abstract

The assessment of the possible role played by the renin-angiotensin system in maintaining arterial hypertension requires an understanding of the mechanisms regulating renin release from the kidney. In addition to intrarenal mechanisms of control, recent investigation stresses the importance of sympathetic influences on the juxtaglomerular cells both in experimental animals and in man. Studies with beta-adrenergic blocking agents, interfering with sympathetic release of renin, and with peptides interfering with sympathetic release of renin, and with peptides interfering with the generation or action of angiotensin II, suggest that renin may play some pressor role in a number of cases of hypertension: a major one in the small group of patients with high plasma renin, and possibly a minor one in the large population of patients whose renin is stimulated by treatment with diuretics and vasodilators. On the whole, available evidence suggests that renin disturbances in essential hypertension are rarely primary. It is unlikely, therefore, that renin levels alone can suffice as guideline for treatment of hypertension. A more comprehensive approach should be based on a multifaceted profile, including but not limited to renin.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 912827     DOI: 10.1161/01.cir.56.5.691

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  22 in total

Review 1.  Renal sympathetic nerve ablation: the new frontier in the treatment of hypertension.

Authors:  Markus P Schlaich; Henry Krum; Paul A Sobotka
Journal:  Curr Hypertens Rep       Date:  2010-02       Impact factor: 5.369

Review 2.  How does renal denervation lower blood pressure and when should this technique be considered for the treatment of hypertension?

Authors:  Kui Toh Gerard Leong; Henry Krum
Journal:  Curr Cardiol Rep       Date:  2013-11       Impact factor: 2.931

3.  Acute cerebral hemorrhage normalized plasma renin activity in a patient with primary aldosteronism.

Authors:  Tetsuya Hiraiwa; Ranko Ibata; Keiji Tanimoto; Naomune Yamamoto; Jungo Terasaki; Haruhito Azuma; Akihisa Imagawa; Toshiaki Hanafusa
Journal:  Endocrine       Date:  2009-10-28       Impact factor: 3.633

4.  Targeting the renin-angiotensin-aldosterone system in fibrosis.

Authors:  Mohammad AlQudah; Taben M Hale; Michael P Czubryt
Journal:  Matrix Biol       Date:  2020-05-16       Impact factor: 11.583

5.  Time-course of the anti-hypertensive action of atenolol: comparison of response to first dose and to maintained oral administration.

Authors:  G Leonetti; L Terzoli; C Bianchini; C Sala; A Zanchetti
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

6.  The effects of alpha-adrenoceptor blockade on dopamine-induced renal vasodilation and natriuresis.

Authors:  A J Smit; S Meijer; H Wesseling; A J Donker; W D Reitsma
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-02       Impact factor: 3.000

Review 7.  Renal nerves in the maintenance of hypertension: a potential therapeutic target.

Authors:  Richard E Katholi; Krishna J Rocha-Singh; Nilesh J Goswami; Paul A Sobotka
Journal:  Curr Hypertens Rep       Date:  2010-06       Impact factor: 5.369

Review 8.  Renal denervation in human hypertension: mechanisms, current findings, and future prospects.

Authors:  Markus P Schlaich; Dagmara Hering; Paul A Sobotka; Henry Krum; Murray D Esler
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

9.  Changes in ventricular size and plasma renin activity after cardiac surgery in children.

Authors:  B D Bourgeois; I Oberhänsli; J C Rouge; L Paunier; B Friedli; M B Vallotton
Journal:  Br Heart J       Date:  1980-09

Review 10.  Renal denervation for refractory ventricular arrhythmias.

Authors:  Jason S Bradfield; Marmar Vaseghi; Kalyanam Shivkumar
Journal:  Trends Cardiovasc Med       Date:  2014-05-29       Impact factor: 6.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.